Clinical Trial Update: Study to Reduce Intravenous Exposures (STRIVE) [Phase 2, Phase 3]

View source ↗

Summary

The STRIVE study, a Phase 2/3 trial sponsored by the National Institute on Drug Abuse (NIDA) to reduce intravenous exposures, targets patients with Hepatitis C …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis C

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Hepatitis C, HIV Infections | Phase 2, Phase 3 | Status: COMPLETED